UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 13.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,630 shares of the company’s stock after selling 10,616 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.13% of EyePoint Pharmaceuticals worth $548,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Deerfield Management Company L.P. Series C raised its position in EyePoint Pharmaceuticals by 51.4% during the second quarter. Deerfield Management Company L.P. Series C now owns 877,790 shares of the company’s stock worth $7,637,000 after acquiring an additional 298,196 shares during the period. Fiera Capital Corp lifted its position in shares of EyePoint Pharmaceuticals by 0.9% in the second quarter. Fiera Capital Corp now owns 677,038 shares of the company’s stock valued at $5,890,000 after acquiring an additional 5,920 shares in the last quarter. Perceptive Advisors LLC raised its holdings in EyePoint Pharmaceuticals by 8.6% in the 2nd quarter. Perceptive Advisors LLC now owns 640,274 shares of the company’s stock valued at $5,570,000 after acquiring an additional 50,628 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in EyePoint Pharmaceuticals in the 2nd quarter worth approximately $5,488,000. Finally, Cubist Systematic Strategies LLC lifted its position in EyePoint Pharmaceuticals by 842.5% during the second quarter. Cubist Systematic Strategies LLC now owns 476,250 shares of the company’s stock worth $4,143,000 after buying an additional 425,717 shares in the last quarter. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Jefferies Financial Group started coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a “buy” rating and a $15.00 price target for the company. Scotiabank initiated coverage on EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 target price for the company. Robert W. Baird cut their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, November 11th. HC Wainwright reiterated a “buy” rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research note on Thursday, December 5th. Finally, StockNews.com raised shares of EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st. One research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $25.71.

EyePoint Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ EYPT opened at $7.10 on Friday. The company’s 50-day moving average price is $9.74 and its 200 day moving average price is $9.12. EyePoint Pharmaceuticals, Inc. has a 52 week low of $6.90 and a 52 week high of $30.99. The stock has a market cap of $484.58 million, a price-to-earnings ratio of -3.55 and a beta of 1.45.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.